ArticlePakistan journal of medical sciences2026
Vonoprazan in erosive esophagitis: Influence of gender and hiatus hernia on outcomes.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to determine the efficacy of vonoprazan in erosive esophagitis and association of gender and hiatus hernia with treatment outcomes. Methodology: This prospective single arm cohort study (before and after treatment) was conducted from 1 Results: The mean age was 42.51±8.19 years, with 120 (54.5%) male and 100 (45.5%) female. Before treatment, 115(52.3%) had LA-C and 26(11.8%) had LA-D esophagitis. Following treatment, 191(86.8%) out of 220 patients had no esophagitis, 18(8.2%) had LA-A and 11(5%) had LA-B esophagitis (OR:6.59, 95%CI 4.45 - 9.73, p < 0.001). Complete healing rates were similar in male and female patients (p = 0.94). Among 58 patients having hiatus hernia, 35(60.34%) had no esophagitis post-treatment as compared to those without hernia where 156 out of 162 (96.29%) had no esophagitis post-treatment (OR:17.08, CI (6.47- 45.08), p < 0.001). Conclusion: Vonoprazan demonstrated high efficacy in healing erosive esophagitis, especially in patients without hiatus hernia while having similar efficacy in both genders. These findings highlight vonoprazan's therapeutic potential in management of erosive esophagitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.